19-Oct-2026 19:53:27
ROSSARI BIOTECH Q2 CONCALL : MID-TO-HIGH-TEEN REVENUE GROWTH, FY28 MARGIN EXPANSION & SAUDI ARABIA MANUFACTURING PLANS
• FY27 REVENUE GROWTH EXPECTED IN MID-TO-HIGH TEENS • FY27 EBITDA MARGIN EXPECTED AROUND 12%; MEANINGFUL IMPROVEMENT ANTICIPATED FROM FY28 • EXPORT CONTRIBUTION TARGETED ABOVE 30% OF TOTAL REVENUE BY FY27-END • NEW ETHOXYLATION FACILITY OPERATING AT 30% UTILIZATION; IMPROVEMENT EXPECTED BY Q2–Q3 FY28 • RECENTLY COMMISSIONED CAPACITIES EXPECTED TO REACH PEAK UTILIZATION AROUND FY28-END • ADDITIONAL ETHYLENE OXIDE SUPPLY FROM RELIANCE POSSIBLE FROM Q1 FY28; ALLOCATION NOT CONFIRMED • H2 FY27 CAPEX PLANNED AT ₹50–75 CR; DOMESTIC CAPEX EXPECTED TO DECLINE SIGNIFICANTLY IN FY28 • SAUDI ARABIA SPECIALTY CHEMICALS PLANT PLANNED; PROJECT DETAILS EXPECTED TO DEVELOP OVER NEXT 8–12 MONTHS • PHARMA EXCIPIENTS, AROMA CHEMICALS & BIOSURFACTANTS EXPECTED TO SUPPORT HIGHER MARGINS • INSTITUTIONAL & B2C BUSINESS EXPECTED TO REMAIN EBITDA-POSITIVE IN H2 FY27; FULL-YEAR BREAK-EVEN TARGETED • WORKING CAPITAL TARGETED AT 87–90 DAYS BY MARCH 2027 • WORKING-CAPITAL BORROWINGS TARGETED FOR ELIMINATION AROUND MID-FY28; LONG-TERM DEBT EXCLUDED • FREIGHT INFLATION, RAW MATERIAL COSTS & ETHYLENE OXIDE SUPPLY CONSTRAINTS REMAIN KEY RISKS
ROSSARI BIOTECH LIMITED